Edinburgh-based immune-metabolic company Kynos Therapeutics has appointed Dr Alison Strutt as chief finance officer.
She will combine her current role as chief operating officer at NodThera while supporting Kynos.
Strutt formerly held a number of senior finance roles at GSK, including as chief of staff to the chief finance officer, where she was responsible for transforming GSK’s financial reporting processes and organisation, as well as leading local completions of the global Novartis transaction.
